A 5-year-old girl from Delhi presents with progressive gait disturbance, hepatosplenomegaly, and bone pain. Biochemical analysis shows elevated acid phosphatase and chitotriosidase. Bone marrow biopsy shows Gaucher cells (wrinkled tissue paper appearance). Genetic testing confirms homozygous GBA mutation. What is the most appropriate next step in management?

Explanation

## Clinical Context: Gaucher Disease Type 1 (Non-Neuronopathic) This child presents with classic features of **Gaucher disease**: - Hepatosplenomegaly (most common finding) - Bone involvement (bone pain, pathological fractures) - Elevated acid phosphatase and chitotriosidase (biomarkers) - Gaucher cells on bone marrow biopsy (pathognomonic: glucocerebroside-filled macrophages with "wrinkled tissue paper" appearance) - GBA gene mutation (confirmed genetic diagnosis) ## Management Algorithm for Gaucher Disease Type 1 ```mermaid flowchart TD A[Gaucher Disease Type 1 Confirmed]:::outcome --> B{Symptomatic?}:::decision B -->|Mild/Asymptomatic| C[Observation + Monitoring]:::action B -->|Moderate-Severe| D[Disease-Modifying Therapy]:::action D --> E{First-line choice?}:::decision E -->|Enzyme Replacement Therapy| F[Imiglucerase IV infusion]:::action E -->|Substrate Reduction Therapy| G[Miglustat or Eliglustat oral]:::action F --> H[Monitor: Organomegaly, bone markers, chitotriosidase]:::action G --> H I[Splenectomy]:::urgent --> J[Reserved for specific indications]:::outcome J --> K[Recurrent splenic infarcts or severe thrombocytopenia]:::outcome ``` **Key Point:** The **first-line treatment** for symptomatic Gaucher disease Type 1 is **disease-modifying therapy**: either enzyme replacement therapy (ERT) or substrate reduction therapy (SRT). ### Why ERT/SRT is the Correct Answer 1. **Imiglucerase (ERT)** - Recombinant glucocerebrosidase - IV infusion every 2 weeks - Reduces organomegaly, improves bone disease, normalizes biomarkers - Gold standard for symptomatic disease 2. **Miglustat or Eliglustat (SRT)** - Inhibits glucosylceramide synthase (reduces substrate accumulation) - Oral administration (miglustat) or eliglustat (substrate-dependent dosing) - Alternative if ERT unavailable or contraindicated - Slower onset but effective 3. **This patient is symptomatic** (gait disturbance, bone pain, organomegaly) and requires treatment initiation. **Clinical Pearl:** Biomarkers (acid phosphatase, chitotriosidase, angiotensin-converting enzyme) guide treatment response monitoring. Chitotriosidase is particularly sensitive for disease burden. ### Comparison of Treatment Options | Feature | ERT (Imiglucerase) | SRT (Miglustat/Eliglustat) | |---------|-------------------|---------------------------| | Route | IV infusion | Oral | | Onset | Faster (weeks) | Slower (months) | | Organomegaly reduction | Excellent | Good | | Bone disease improvement | Yes | Modest | | CNS penetration | No | Yes (miglustat) | | Cost | High | Moderate | | Use in Type 3 | Limited | Better (CNS involvement) | **High-Yield:** Type 1 Gaucher disease is the **only lysosomal storage disorder with proven disease-modifying therapy**. This is a frequently tested distinction. ### Why Other Options Are Incorrect | Option | Why Wrong | |--------|----------| | Splenectomy | Historically used but now reserved for specific indications (recurrent splenic infarcts, severe thrombocytopenia unresponsive to therapy). Not first-line. | | Corticosteroids | No role in Gaucher disease. May worsen immunosuppression. | | BMT | Considered only in severe, refractory disease or Type 3 with neurological progression. Not first-line. | **Mnemonic:** **ERTSRT** — **E**nzyme **R**eplacement **T**herapy or **S**ubstrate **R**eduction **T**herapy for symptomatic Gaucher Type 1.